Published in Crit Care on May 29, 2014
Performance of Cystatin C- and Creatinine-Based Estimated Glomerular Filtration Rate Equations Depends on Patient Characteristics. Clin Chem (2015) 1.48
Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. Crit Care (2014) 0.87
Estimation of creatinine clearance using plasma creatinine or cystatin C: a secondary analysis of two pharmacokinetic studies in surgical ICU patients. BMC Anesthesiol (2015) 0.78
Estimated GFR and cystatin C for drug dosing: moving beyond proof of concept to clinical translation? Am J Kidney Dis (2014) 0.78
A New Equation to Estimate Muscle Mass from Creatinine and Cystatin C. PLoS One (2016) 0.76
Clinical decision support for drug related events: Moving towards better prevention. World J Crit Care Med (2016) 0.75
Cystatin C Falsely Underestimated GFR in a Critically Ill Patient with a New Diagnosis of AIDS. Case Rep Nephrol (2016) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition (1992) 16.89
Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med (2012) 14.99
The threat to medical-records research. N Engl J Med (1997) 8.50
Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis (2012) 7.97
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm (2009) 7.43
Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis (2011) 6.71
Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int (2008) 5.90
Glomerular filtration rate estimated by cystatin C among different clinical presentations. Kidney Int (2006) 4.59
Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. Ann Intern Med (1981) 2.68
The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis (2006) 2.68
Reduced production of creatinine limits its use as marker of kidney injury in sepsis. J Am Soc Nephrol (2009) 2.61
Vancomycin: a history. Clin Infect Dis (2006) 2.52
Estimating GFR among participants in the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis (2012) 2.42
Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med (2012) 2.38
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
The epidemiology of intravenous vancomycin usage in a university hospital. A 10-year study. JAMA (1993) 2.18
Standardization of Cystatin C: development of primary and secondary reference preparations. Scand J Clin Lab Invest Suppl (2008) 2.11
Historical yearly usage of vancomycin. Antimicrob Agents Chemother (1998) 1.83
Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis (2003) 1.74
Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. Kidney Int (2013) 1.66
Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med (1988) 1.53
Decreased rate of creatinine production in patients with hepatic disease: implications for estimation of creatinine clearance. Ther Drug Monit (1983) 1.24
Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines. Pharmacotherapy (2011) 1.20
Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother (2012) 1.04
Cystatin C as a marker of glomerular filtration rate: prospects and limitations. Curr Opin Nephrol Hypertens (2011) 1.04
The role of cystatin C in improving GFR estimation in the general population. Am J Kidney Dis (2011) 0.95
Detection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine. BMC Nephrol (2014) 0.94
Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem (2007) 0.92
Predicting the glomerular filtration rate from serum creatinine, serum cystatin C and the Cockcroft and Gault formula with regard to drug dosage adjustment. Int J Clin Pharmacol Ther (2004) 0.92
Acute renal problems in the critically ill cancer patient. Curr Opin Crit Care (2008) 0.91
Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit (2006) 0.91
Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother (2009) 0.88
Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J (2012) 0.87
Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C. Int J Antimicrob Agents (2010) 0.87
Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci (2013) 0.87
Acute kidney injury in the critically ill, morbidly obese patient: diagnostic and therapeutic challenges in a unique patient population. Crit Care Clin (2010) 0.83
Hoek's formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin. Int J Clin Pharmacol Ther (2007) 0.82
Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther Drug Monit (2007) 0.81
Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin. J Clin Pharm Ther (2013) 0.78
Current issues in measurement and reporting of urinary albumin excretion. Clin Chem (2008) 2.98
Noninvasive differentiation of uric acid versus non-uric acid kidney stones using dual-energy CT. Acad Radiol (2007) 2.80
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. Clin Infect Dis (2010) 2.54
Relative performance of the MDRD and CKD-EPI equations for estimating glomerular filtration rate among patients with varied clinical presentations. Clin J Am Soc Nephrol (2011) 2.47
Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med (2011) 2.42
For estimating creatinine clearance measuring muscle mass gives better results than those based on demographics. Kidney Int (2009) 2.32
Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. Urology (2011) 2.26
Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.22
Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation (2013) 2.10
Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis (2005) 2.02
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Demographic and clinical characteristics associated with glomerular filtration rates in living kidney donors. Kidney Int (2009) 1.99
Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility. Arch Dermatol (2006) 1.93
Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol (2011) 1.92
Prevalence of renal artery and kidney abnormalities by computed tomography among healthy adults. Clin J Am Soc Nephrol (2010) 1.91
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Clinical characteristics of potential kidney donors with asymptomatic kidney stones. Nephrol Dial Transplant (2011) 1.87
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney Int (2013) 1.84
Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension (2007) 1.79
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis. Kidney Int (2013) 1.79
Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma (2010) 1.78
Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol (2006) 1.75
Chronic renal dysfunction late after liver transplantation. Liver Transpl (2002) 1.74
Urinalysis is more specific and urinary neutrophil gelatinase-associated lipocalin is more sensitive for early detection of acute kidney injury. Nephrol Dial Transplant (2012) 1.71
A critical evaluation of chronic kidney disease--should isolated reduced estimated glomerular filtration rate be considered a 'disease'? Nephrol Dial Transplant (2008) 1.70
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int (2012) 1.68
Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated with chronic kidney disease. Kidney Int (2013) 1.66
Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery (2011) 1.64
Hereditary causes of kidney stones and chronic kidney disease. Pediatr Nephrol (2013) 1.64
Myeloproliferative neoplasms cause glomerulopathy. Kidney Int (2011) 1.62
Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med (2006) 1.61
Characteristics of renal cystic and solid lesions based on contrast-enhanced computed tomography of potential kidney donors. Am J Kidney Dis (2012) 1.59
Temporal trends in incidence of kidney stones among children: a 25-year population based study. J Urol (2012) 1.59
Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol (2011) 1.58
Kidney function and risk triage in adults: threshold values and hierarchical importance. Kidney Int (2010) 1.57
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol (2011) 1.57
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves. Am J Physiol Heart Circ Physiol (2004) 1.55
Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma (2008) 1.54
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
Feasibility of discriminating uric acid from non-uric acid renal stones using consecutive spatially registered low- and high-energy scans obtained on a conventional CT scanner. AJR Am J Roentgenol (2015) 1.51
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
Urinary oxalate excretion increases in home parenteral nutrition patients on a higher intravenous ascorbic acid dose. JPEN J Parenter Enteral Nutr (2004) 1.49
Estimating glomerular filtration rate in Asian subjects: where do we stand? Kidney Int (2011) 1.47
Performance of flow cytometry to screen urine for bacteria and white blood cells prior to urine culture. Clin Biochem (2013) 1.47
State of the art for measurement of urine albumin: comparison of routine measurement procedures to isotope dilution tandem mass spectrometry. Clin Chem (2013) 1.47
Development and validation of GFR-estimating equations using diabetes, transplant and weight. Nephrol Dial Transplant (2009) 1.46
Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int (2012) 1.45
Risk factor profile for chronic kidney disease is similar to risk factor profile for small artery disease. J Hypertens (2011) 1.45
Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol (2010) 1.44
Cystone® for 1 year did not change urine chemistry or decrease stone burden in cystine stone formers. Urol Res (2010) 1.42
Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol (2010) 1.42
Dual-energy dual-source CT with additional spectral filtration can improve the differentiation of non-uric acid renal stones: an ex vivo phantom study. AJR Am J Roentgenol (2011) 1.41
Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response. Haematologica (2007) 1.40
Automated urinalysis in the clinical lab. MLO Med Lab Obs (2012) 1.39
Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer (2007) 1.38
Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol (2011) 1.34
How I treat monoclonal gammopathy of renal significance (MGRS). Blood (2013) 1.33
Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis (2009) 1.32
Fibrillary glomerulonephritis: a report of 66 cases from a single institution. Clin J Am Soc Nephrol (2011) 1.29
Cell biology of pathologic renal calcification: contribution of crystal transcytosis, cell-mediated calcification, and nanoparticles. J Investig Med (2006) 1.29
GFR estimation in Japan and China: what accounts for the difference? Am J Kidney Dis (2009) 1.28
C3 glomerulonephritis associated with monoclonal gammopathy: a case series. Am J Kidney Dis (2013) 1.24
Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int (2010) 1.24
A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension (2012) 1.23
Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein. Am J Physiol Renal Physiol (2010) 1.22
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma. Cancer (2011) 1.20
Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. Am J Kidney Dis (2012) 1.19
Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol (2013) 1.19
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood (2011) 1.19
Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol (2007) 1.18
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis. Am J Hematol (2011) 1.17
Association of kidney function and metabolic risk factors with density of glomeruli on renal biopsy samples from living donors. Mayo Clin Proc (2011) 1.15
Urolithiasis and the risk of ESRD. Clin J Am Soc Nephrol (2012) 1.15
Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc (2008) 1.13
Nephrolithiasis and loss of kidney function. Curr Opin Nephrol Hypertens (2013) 1.11
Chronic renovascular hypertension is associated with elevated levels of neutrophil gelatinase-associated lipocalin. Nephrol Dial Transplant (2012) 1.11
Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant (2008) 1.10
Do we need another equation to estimate GFR from serum creatinine in renal allograft recipients? Nephrol Dial Transplant (2008) 1.10
Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol (2010) 1.10
VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep (2012) 1.10
Acute kidney injury after transcatheter aortic valve replacement: a systematic review and meta-analysis. Am J Nephrol (2015) 1.10
Annexin II is present on renal epithelial cells and binds calcium oxalate monohydrate crystals. J Am Soc Nephrol (2003) 1.09
Smoldering multiple myeloma requiring treatment: time for a new definition? Blood (2013) 1.09
Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis (2005) 1.09